|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed that CD1d was predominantly expressed on DCs in 3LL tumor‑bearing mice, whilst a deficiency of CD1d promoted tumor growth.
|
30864713 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The CD1d- and PJA2-related tumour microenvironment might be crucial for IMPC.
|
30651076 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a mouse PCa model, iNKT cells restrained the pro-angiogenic and immunosuppressive capabilities of tumor-infiltrating immune cells by reducing pro-angiogenic TIE2<sup>+</sup>, M2-like macrophages (TEMs), and sustaining pro-inflammatory M1-like macrophages. iNKT cells directly contacted macrophages in the PCa stroma, and iNKT cell transfer into tumor-bearing mice abated TEMs, delaying tumor progression. iNKT cells modulated macrophages through the cooperative engagement of CD1d, Fas, and CD40, which promoted selective killing of M2-like and survival of M1-like macrophages.
|
29539427 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
They can mediate anti-tumor immunity by direct recognition of tumor cells that express CD1d, and/or via targeting CD1d found on cells within the tumor microenvironment.
|
29559971 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunotherapies that target CD1d-restricted invariant NKT (iNKT) cells can prevent tumor growth in murine models but trials in humans have shown limited clinical efficacy.
|
29872551 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Invariant natural killer T (iNKT) cells produce copious amounts of cytokines in response to T-cell receptor (TCR) stimulation by recognizing antigens such as α-galactosylceramide (α-GalCer) presented on CD1d; thus, orchestrating other immune cells to fight against pathogen infection and tumors.
|
30245690 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cytokine-mediated and CD1d-dependent interactions between iNKT cells and myeloid and lymphoid cells enable iNKT cells to contribute to the activation of multiple cell types, with important impacts on host immunity to infection and tumors and on the prevention of autoimmunity.
|
29967611 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Invariant natural killer T (iNKT) cells are a small population of lymphocytes with unique specificity for glycolipid antigens presented by non-polymorphic CD1d receptor on dendritic cells (DCs). iNKT cells play a central role in tumor immunology since they are implicated in the coordination of innate and adaptive immune responses.
|
28549432 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Delayed tumor growth is dependent on CD1d expression by host immune cells, as shown in experiments engaging CD1d knockout mice.
|
27787577 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Systemic treatments with the CD1d-antitumor fusion proteins loaded with the agonist alpha-galactosylceramide (αGalCer) led to specific iNKT cell activation, resulting in a sustained growth inhibition of established tumors expressing HER2 or CEA, while treatment with the free αGalCer was ineffective.
|
29163493 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By immunohistochemistry, we found that CD1d expression significantly associated with tumour stage/grade, higher relapse rates, poorer cancer-specific and overall survival.
|
25477528 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Invariant natural killer T (iNKT) cells are CD1d restricted-T cells that react to lipid antigens. iNKT cells were shown to be important in infection, autoimmunity and tumor surveillance.
|
25479931 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
|
25115738 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, CD1d is expressed on tumor cells in a subset of MB patients and represents a novel target for immunotherapy.
|
23891738 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results of this study emphasize the importance of determining the CD1d expression status of the tumor when tailoring NKT-based immunotherapies for the prevention and treatment of metastatic breast cancer.
|
21695190 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, this work provides evidence linking a novel function of CD1d in the regulation of cell death with tumor survival and progression in humans.
|
19056691 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although NKTs can be directly cytotoxic against CD1d+ cells, the majority of human tumors are CD1d-.
|
19411762 |
2009 |